Bladder cancer represents one of the most common urologic malignancies, with a significant incidence especially in the male population over 60 years of age. However, in addition to the clinical and psychological impact on the patient, this condition also has a significant economic burden on the health care system and society as a whole. This article analyzes the economic burden of bladder cancer, with a focus on the direct and indirect costs associated with the disease.

According to the most recent data, bladder cancer is the tenth most diagnosed cancer worldwide, with a particularly high prevalence in industrialized countries. In Italy, more than 29,000 new cases per year are estimated, and the high prevalence is also due to the high recurrence rate that characterizes the disease, making it one of the neoplasms with the most expensive long-term follow-up.

Direct costs of bladder cancer include all health care costs incurred for diagnosis (cytology examinations, cystoscopy, imaging), treatment (surgery, immunotherapy, chemotherapy) and follow-up. The peculiarity of this pathology is the need for frequent and prolonged follow-ups over time, especially in cases of non-muscle-invasive cancer (NMIBC), which although less aggressive, tend to recur frequently.

A study published in the Journal of Urology estimated that bladder cancer is among the cancers with the highest lifetime cost per patient, with annual expenditures to the national health care system exceeding 5 billion euros in Europe alone. In Italy, annual direct costs can range from 3,000 to more than 10,000 euros per patient, depending on staging and frequency of recurrence.

In addition to medical expenses, there are indirect costs that are often underestimated. These include lost work productivity of the patient and caregivers, days away from work, early retirement, and costs related to disability or functional limitation.

In working-age patients, bladder cancer can have a major impact on employment and income. Even in older patients, the need for ongoing care places a significant burden on families, who are often forced to rely on home support or residential facilities.

In light of these data, the need for healthcare strategies aimed at optimizing resources is evident. The introduction of shared diagnostic-therapeutic protocols, the use of less invasive technologies, the personalization of follow-up, the adoption of newer, more effective immunotherapy drugs, and especially the adoption of screening programs through urine cytology can help reduce long-term costs while improving patient quality of life.

In addition, investments in primary prevention (smoking reduction, exposure to carcinogens) and secondary prevention (screening for at-risk groups) can be crucial tools to decrease the incidence and severity of the disease.

Bladder cancer poses a major challenge not only clinically but also economically. Its impact on health care spending is among the highest among malignancies, mainly due to the long duration of follow-up and high recurrence rate. Better allocation of resources, based on scientific evidence and multidisciplinary care, can help contain costs and improve outcomes for patients and the community.